This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Veterinary BRAF Therapeutic Antibody Development
In today's veterinary treatment landscape, innovative therapeutic strategies, particularly therapeutic antibodies, have altered the treatment paradigm for many diseases. To maintain this exhilarating progression, there is a continuous need to develop new, validated, and functionally effective targets. BioVenic offers the service for veterinary BRAF therapeutic antibody development, leveraging our diverse platform for veterinary therapeutic antibody development. This service aims to facilitate the development of therapeutic antibodies against the crucial target BRAF, promoting the field of animal health.
Background of BRAF
| Full Name | B-Raf proto-oncogene, serine/threonine kinase. |
|---|---|
| Aliases | NS7, B-raf, BRAF1, RAFB1, B-RAF1, BRAF-1. |
| Target Profile | BRAF encoding the protein in the RAF serine/threonine-protein kinase family plays a crucial role in cell division, growth, and differentiation. If BRAF mutates, it ceases to function normally, sending uncontrolled cell division signals, and leading to tumor formation. Abnormal activation of BRAF is often associated with the development of cancer in animals. |
MoA of BRAF
The BRAF protein is an upstream regulator in the RAS-RAF-MEK-ERK signaling pathway. Its activation is typically triggered by ligands such as growth factors, leading to the phosphorylation of downstream MAPK/ERK kinase (MEK) proteins and subsequent extracellular signal-regulated kinases (ERK). The activated ERK, through phosphorylation, transmits extracellular signals to the cell nucleus, causing changes in gene transcription levels, thereby regulating vital cellular physiological activities such as cell proliferation, survival, and growth. In pathological states, abnormal activation of BRAF (such as through mutations) results in an encoded product that is several times more active than the wild type, leading to aberrant activation of the MAPK pathway. Consequently, this can promote excessive cell proliferation even in the absence of cytokines and other stimulating factors, leading to tumor development. Conversely, inhibiting the activity of BRAF can block this signaling pathway, thereby inhibiting tumor growth.
Fig.1 Schematic diagram of mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK) pathway.1,2
Application in Veterinary Therapeutics
Within animals, the abnormal activation and overexpression of BRAF are often associated with the development of cancers, such as canine transitional cell carcinoma (also known as urothelial carcinoma), and prostatic carcinoma, as well as feline diffuse iris melanoma. DNA sequencing of TCC tumor cells has revealed that 65-85% of cases exhibit a BRAF gene V595E mutation.
Veterinary BRAF Therapeutic Antibody Development Services
Given the high incidence of BRAF mutations in these types of cancers, therapies targeting the BRAF/MAPK pathway may offer a new treatment option for animals suffering from cancers associated with BRAF mutations. Leveraging our diverse and emerging technology platform, BioVenic offers specialized services in therapeutic BRAF antibody research and development. We assist you in developing veterinary therapeutic antibodies that specifically bind to and modulate the activity of BRAF, providing animals with safer and more effective treatment options. Additionally, our services include antibody characterization and engineering to ensure that the developed veterinary BRAF therapeutic antibodies achieve optimal therapeutic effects.
For detailed information about how to develop the veterinary BRAF therapeutic antibody, please click the link below.
Fig.2 Antibody discovery and production methods: from mouse hybridoma to transgenic mice. (BioVenic Original)
Why Choose Us?
Customized service solutions tailored to your specific needs, encompassing the entire process from antibody screening, to preparation and engineering, providing comprehensive service options for your consideration.
Diverse platforms for the development of veterinary therapeutic antibodies, offering a choice between traditional and emerging technologies.
Strict adherence to quality control standards to ensure the safety and effectiveness of the final antibody samples, aiding in advancing your research progress.
The BRAF gene plays a crucial role in various animal cancers, especially those associated with BRAF mutations, such as canine transitional cell carcinoma. BioVenic's service in veterinary BRAF therapeutic antibody development targeting not only covers the complete preparation process but also includes precise optimization to ensure high affinity and specificity. If you are considering developing BRAF-targeted antibodies for animal cancer treatment, please contact us. Let us assist you in veterinary BRAF therapeutic antibody development.
Reference
- Mochizuki, Hiroyuki, and Matthew Breen. "Comparative aspects of BRAF mutations in canine cancers." Veterinary sciences 2.3 (2015): 231-245.
- Image retrieved from Figure 1 "Mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK) pathway.", Mochizuki, Hiroyuki, and Matthew Breen, 2015, used under [CC BY 4.0], the image title was changed to "Schematic diagram of mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK) pathway."